期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性肾损伤中连续性高剂量肾脏替代治疗的荟萃分析 被引量：3

Meta-analysis of high dose continuous renal replacement therapy for acute kidney injury
下载PDF
导出
摘要 目的评价在急性肾损伤中使用连续性高剂量肾脏替代治疗是否可以降低患者的病死率。方法检索了PubMed/MEDLINE、EMBASE和Cochrane Library电子数据库的急性肾损伤中使用连续性高剂量肾脏替代治疗的随机对照试验(randomized controlled trials,RCT),使用优势比进行计算。结果共分析6组研究,2522例患者纳入本次研究,与常规剂量组相比,连续性高容量肾脏替代治疗不能降低患者的存活率(OR=1.10,95%CI:0.93～1.30,P=0.002,I2=73.0%),不能缩短平均住院日,但可以明显改善肾脏恢复。结论连续性高容量肾脏替代治疗仅仅能够改善肾脏恢复,在改善存活率与缩短平均住院日上并不能取得更多的益处。 Objective To evaluate the effect of high dose continuous renal replacement therapy for acute kidney injury patients. Methods The rrandom controlled clinical trial （RCT） aimed to evaluate the effect of high dose continuous renal replacement therapy for acute kidney injury were searched on the Pubmed/Medline,EMBASE and Cochrane Library electronic databases,then the odds ratio was calculated. Results 2522 patients in 6 RCT were included in this study,the effect of survival rate was compared in the high dose and regular dose group. Compared with the regular dose group,the survival rate of high dose group was not improved （OR=1.10 95%CI（0.93,1.30）P = 0.002,I2=73.0%）. Further analysis showed that the renal survival might be improved in the high dose group. Conclusion Compared with the regular dose,high dose continuous renal replacement therapy can not change the overall survival rate,hospitalization stay,but may improve the survival of the kidney.
作者 隋准 王磊 王梅
机构地区 北京大学人民医院肾内科
出处 《北京医学》 CAS 2011年第2期106-110,共5页 Beijing Medical Journal
关键词 连续性高容量肾脏替代治疗 急性肾损伤 META分析 High dose continuous renal replacement therapy Acute kidney injury Meta analysis
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

  • 1Bagshaw SM, Berthlaume LR, Delaney A, et al. Continuousversa8 intermittent renal replacement therapy for critically ill patients with acute kidney injury:a meta analysis.Crit Care Med,2008,36:610-617.
  • 2Bellomo R, Ronco C. Continuous haemofihration in the intensive care unit. Crit Care,2000,4:339-345.
  • 3Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis close to continuous hemofiltration increases survival in patients with acute renal failure. Kid Int,2006,70:1312-1317.
  • 4Bagshaw SM, Uehino S, Bellomo R, et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care,2009,24:129-140.
  • 5Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high -volume continuous venovenous hemofihration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med,2002,30:2205-2211.
  • 6Faulhaber-Walter R, Hafer C, Jahr N, et al. The Hannover Dialysis Outcome study: Comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Trans,2009,24:2179-2186.
  • 7Palevsky PM. Renal support in acute kidney injury--how much is enough? N Eng J Med,2009,361:1699-1701.
  • 8Parmu N, Klarenbach S, Wiebe N, et al. Renal replacement therapy in patients with acute renal fmlure:a systematic review. JAMA,2008,299:793-805.

同被引文献40

  • 1Lameire N, Van BW, Vanholder R. The changing epidemiology of acute renal failure[J]. Nat Clin Pract Nephrol, 2006, 2:364-377.
  • 2Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically illpatients:a multinational, multicenterstudy [J]. JA- MA, 2005, 294:813-818.
  • 3Mattes WB, Walker EC. Translational toxicology and thework of the predictive safety testing consortiu [J]. Clin Pharmacol Ther, 2009, 85:327-330.
  • 4Rouse RL, Zhang J, Stewart SR. Comparative profile of commer- cially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats [J]. Kidney Int, 2011, 79: 1186-1197.
  • 5Prozialeck WC, Edwards JR. Early biomarkers of cadmiumexpo- sure and nephrotoxicity[J]. Biometals, 2010, 23:795-809.
  • 6Ling W, Zhao HN, Ben H, et al. Urinary IL- 18 and NGAL as early predictive biomarkers in contrast-induced nephropathy 'after coronary angiography[J]. Nephron Clin Pract, 2008, 108:176-181.
  • 7Bachorzewska, Gajewska H, Malyszko J, et al. NGAL(neutrophil gelatinaseassociated lipocalin) and cystatin C:are they good pre- dictors of contrast nephropathy after percutaneous coronary inter- ventions in patients with stable angina and normal serum creati- nine? [J]. Int J Cardiol, 2008, 127:290-291.
  • 8Shavit L, Dolgoker I, Ivgi H, et al. Neutrophil gelatinase-associ-ated lipocalin as a predictor of complications and mortality in pa- tients undergoing non-cardiac major surgery [J]. Kidney Blood Press Res, 2011, 34:116-124.
  • 9Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury [J]. Clin J Am Soc Nephrol, 2010, 5:2154-2165.
  • 10Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase associ- ated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery[J]. Lancet, 2005, 365:1231-1238.

引证文献3

二级引证文献7

北京医学
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部